Abstract
In May 2011, hepatitis C virus (HCV) protease inhibitors (PIs) were approved by the US Food and Drug Administration to treat persons with genotype 1 chronic hepatitis C virus (HCV) infection, but not those dually infected with human immunodeficiency virus (HIV). Although critical safety and efficacy data are lacking, the availability of the drugs and substantial medical need justify the off-label use of HCV PIs in select HIV/HCV-coinfected persons. Pending results of ongoing investigations, this article represents provisional guidance on the use of HCV PIs in HIV-infected persons.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Antiviral Agents / administration & dosage*
-
Antiviral Agents / adverse effects
-
Antiviral Agents / pharmacokinetics
-
Genotype
-
Guidelines as Topic
-
HIV Infections / complications*
-
Hepacivirus / classification
-
Hepacivirus / genetics
-
Hepatitis C, Chronic / drug therapy*
-
Hepatitis C, Chronic / virology
-
Humans
-
Oligopeptides / administration & dosage
-
Oligopeptides / adverse effects
-
Oligopeptides / pharmacokinetics
-
Proline / administration & dosage
-
Proline / adverse effects
-
Proline / analogs & derivatives
-
Proline / pharmacokinetics
-
Protease Inhibitors / administration & dosage*
-
Protease Inhibitors / adverse effects
-
Protease Inhibitors / pharmacokinetics
-
United States
Substances
-
Antiviral Agents
-
Oligopeptides
-
Protease Inhibitors
-
telaprevir
-
N-(3-amino-1-(cyclobutylmethyl)-2,3-dioxopropyl)-3-(2-((((1,1-dimethylethyl)amino)carbonyl)amino)-3,3-dimethyl-1-oxobutyl)-6,6-dimethyl-3-azabicyclo(3.1.0)hexan-2-carboxamide
-
Proline